Corticosteroids for Multiple Sclerosis: I. Application for Treating Exacerbations

Elliot Frohman, Anjali Shah, Eric Eggenberger, Luanne Metz, Robert Zivadinov, Olaf Stuve

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disorder characterized by a multiphasic course of neurological exacerbations, periods of clinical remission, and, in most patients, ultimately progressive deterioration of functional capabilities. The relapsing-remitting phase of the disease involves acute interruption in neurological functioning relating to areas of inflammation in discrete central-tract systems. The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community. Although there is scientific rationale supporting application of these agents for this purpose, the broad diversity of approaches to using these drugs in clinical practice is a derivative of expert opinion and anecdotal experience. Ultimately, the treatment of MS-related exacerbations is part science, but mostly art. This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients.

Original languageEnglish (US)
Pages (from-to)618-626
Number of pages9
JournalNeurotherapeutics
Volume4
Issue number4
DOIs
StatePublished - Oct 2007

Fingerprint

Multiple Sclerosis
Adrenal Cortex Hormones
Expert Testimony
Demyelinating Diseases
Acute Disease
Art
Neurology
Adrenocorticotropic Hormone
Anti-Inflammatory Agents
Pharmacology
Inflammation
Therapeutics
Pharmaceutical Preparations

Keywords

  • ACTH
  • Corticosteroids
  • pulse steroids

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Pharmacology

Cite this

Corticosteroids for Multiple Sclerosis : I. Application for Treating Exacerbations. / Frohman, Elliot; Shah, Anjali; Eggenberger, Eric; Metz, Luanne; Zivadinov, Robert; Stuve, Olaf.

In: Neurotherapeutics, Vol. 4, No. 4, 10.2007, p. 618-626.

Research output: Contribution to journalArticle

Frohman, Elliot ; Shah, Anjali ; Eggenberger, Eric ; Metz, Luanne ; Zivadinov, Robert ; Stuve, Olaf. / Corticosteroids for Multiple Sclerosis : I. Application for Treating Exacerbations. In: Neurotherapeutics. 2007 ; Vol. 4, No. 4. pp. 618-626.
@article{877c447089fe4645931b0547072bc7ad,
title = "Corticosteroids for Multiple Sclerosis: I. Application for Treating Exacerbations",
abstract = "Multiple sclerosis (MS) is an inflammatory demyelinating disorder characterized by a multiphasic course of neurological exacerbations, periods of clinical remission, and, in most patients, ultimately progressive deterioration of functional capabilities. The relapsing-remitting phase of the disease involves acute interruption in neurological functioning relating to areas of inflammation in discrete central-tract systems. The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community. Although there is scientific rationale supporting application of these agents for this purpose, the broad diversity of approaches to using these drugs in clinical practice is a derivative of expert opinion and anecdotal experience. Ultimately, the treatment of MS-related exacerbations is part science, but mostly art. This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients.",
keywords = "ACTH, Corticosteroids, pulse steroids",
author = "Elliot Frohman and Anjali Shah and Eric Eggenberger and Luanne Metz and Robert Zivadinov and Olaf Stuve",
year = "2007",
month = "10",
doi = "10.1016/j.nurt.2007.07.008",
language = "English (US)",
volume = "4",
pages = "618--626",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Corticosteroids for Multiple Sclerosis

T2 - I. Application for Treating Exacerbations

AU - Frohman, Elliot

AU - Shah, Anjali

AU - Eggenberger, Eric

AU - Metz, Luanne

AU - Zivadinov, Robert

AU - Stuve, Olaf

PY - 2007/10

Y1 - 2007/10

N2 - Multiple sclerosis (MS) is an inflammatory demyelinating disorder characterized by a multiphasic course of neurological exacerbations, periods of clinical remission, and, in most patients, ultimately progressive deterioration of functional capabilities. The relapsing-remitting phase of the disease involves acute interruption in neurological functioning relating to areas of inflammation in discrete central-tract systems. The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community. Although there is scientific rationale supporting application of these agents for this purpose, the broad diversity of approaches to using these drugs in clinical practice is a derivative of expert opinion and anecdotal experience. Ultimately, the treatment of MS-related exacerbations is part science, but mostly art. This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients.

AB - Multiple sclerosis (MS) is an inflammatory demyelinating disorder characterized by a multiphasic course of neurological exacerbations, periods of clinical remission, and, in most patients, ultimately progressive deterioration of functional capabilities. The relapsing-remitting phase of the disease involves acute interruption in neurological functioning relating to areas of inflammation in discrete central-tract systems. The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community. Although there is scientific rationale supporting application of these agents for this purpose, the broad diversity of approaches to using these drugs in clinical practice is a derivative of expert opinion and anecdotal experience. Ultimately, the treatment of MS-related exacerbations is part science, but mostly art. This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients.

KW - ACTH

KW - Corticosteroids

KW - pulse steroids

UR - http://www.scopus.com/inward/record.url?scp=34848825438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848825438&partnerID=8YFLogxK

U2 - 10.1016/j.nurt.2007.07.008

DO - 10.1016/j.nurt.2007.07.008

M3 - Article

C2 - 17920542

AN - SCOPUS:34848825438

VL - 4

SP - 618

EP - 626

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 4

ER -